Risk factors of PSA progression and overall survival in patients with localized and locally advanced prostate cancer treated with primary androgen deprivation therapy

Table 2 Results of analysis of PSA-PFS by log-rank test

		No. of patients	No. of PSA progression	5 year PSA-PFS rate	log-Rank
Total		649	161	71.2 %
Age	≤75	265	66	73.9 %
Age	76≤	384	95	69.0 %	0.230
T classification	T1c	189	42	71.8 %
	T2ab	205	37	78.9 %
	T2c	104	36	65.2 %	*
	T3a	103	28	70.1 %
	T3b	48	18	54.0 %
Stage	B	498	115	73.2 %
Stage	C	151	46	64.9 %	0.155
PSA level at diagnosis	<10	197	31	83.2 %
	10-20	195	42	75.2 %	**
	20≤	257	88	59.4 %
Gleason score	6	288	60	76.2 %
	7	196	43	72.0 %	***
	8≤	165	58	61.8 %
Laterality of cancer detected by biopsy	Unilateral	365	66	77.2 %
Laterality of cancer detected by biopsy	Bilateral	284	95	63.8 %	<0.001
SVI	Negative	601	143	72.7 %
SVI	Positive	48	18	54.0 %	0.030

PSA-PFS: PSA progression-free survival
SVI: seminal vesicle involvement
^*: T1c vs. T2c; p = 0.036. T1c vs. T3b; p = 0.028. T2ab vs. T2c; p = 0.001. T2ab vs. T3b; p = 0.003. others; p > 0.05
**: <10 vs. 10–20; p = 0.192. 10–20 vs. 20≤; p = 0.002. <10 vs. 20≤; p < 0.001
***: 6 vs. 7, p = 0.310. 7 vs. 8≤; p = 0.028. 6 vs. 8≤; p = 0.004

ISSN: 1471-2407